Change the keyword or sentiment above, then click Apply.
Wednesday, 16 Sep 20262 updates
↗ AI sentiment: Bullish
59% confidence
Alkem Launches NeuCeno for Epilepsy, Cuts Seizures by 78%
Alkem Laboratories launches NeuCeno (cenobamate) for treating partial-onset seizures in adult patients.
NeuCeno offers advanced epilepsy management, reducing seizure frequency by up to 78%; available in six tablet strengths.
Source: BSE
↗ AI sentiment: Bullish
50% confidence
Alkem Laboratories: Launches Neuceno For Partial-Onset Seizures Treatment In Adults In India, With Once Daily Oral Doses Available.
Tuesday, 15 Sep 20261 update
↔ AI sentiment: Neutral
94% confidence
Alkem Labs Names Dr. Sinha as Senior Exec from Sept 2026
Alkem Laboratories appoints Dr. Shubhadeep Sinha as senior management effective 15th Sept 2026.
Dr. Sinha has 25+ years of experience in healthcare and pharmaceutical fields.
Source: BSE
Friday, 11 Sep 20261 update
↔ AI sentiment: Neutral
66% confidence
Alkem Labs Sees ₹49.6 Cr Block Trade on NSE at ₹5079.5
Alkem Labs' NSE block trade valued Rs. 49.6 Cr for 97,565 shares at Rs. 5079.5.
Source: Livesquawk
Tuesday, 08 Sep 20261 update
↗ AI sentiment: Bullish
54% confidence
Alkem Laboratories: Introduces Renocia Exo™, India's First Patented Ginsenoside Exosome Hair Growth Serum; Combines Various Regenerative Technologies for Hair Follicle Support; Focuses on Tackling Complex Biological Mechanisms Behind Hair Loss.